Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Clinical trial NCT04404283 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04404283
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-20
- Primary completion
- 2026-01-23
- Enrollment
- 239
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.